PAHCPhibro Animal Health Corporation
Is it safe?
Solid, nothing alarming: a safe balance sheet, but big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Some accounting flags, worth a closer look Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -80% · now 35% below its 52-week high.
Unless marked, from SEC EDGAR, as of Jun 30, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can PAHC take a bad year?
Phibro Animal Health Corporation carries $656M of net debt at 2.67× EBITDA: a load its earnings can carry.
Net debt · as at Q4 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 2.67×
Net debt / EBITDA · 3.55× a year ago · the load is coming down
- Altman Z-score
- 2.68
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 4.19×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ4 2026
- $738M
- Cash and short-term investments
- $82M
- Net debt
- $656M
- EBITDA, trailing twelve months
- $246M
- Operating profit, trailing twelve months
- $194M
- Debt / equity
- 1.91×
- Total debt / EBITDA
- 3.00×
- Annualised volatilitytwo years of daily moves
- 52%
- Worst drawdown on file
- −80%
- Below its 52-week high
- 35%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #8 of 41 by RyuScore